Luye Pharma GroupFRA:LUP +3.03%47 PEG Ratio is 1.79 as of Jul. 03, 2026, which is 127% above its 10-year median of 0.79. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 349 Drug Manufacturers companies, Luye Pharma Group ranks worse than 52.44% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Luye Pharma Group's PEG Ratio or its related term are showing as below:
FRA:LUP'
s PEG Ratio Range Over the Past 10 Years
Min: 0.39 Med: 0.79 Max: 5.22
Current: 1.93
During the past 13 years, Luye Pharma Group's highest PEG Ratio was 5.22. The lowest was 0.39. And the median was 0.79.
FRA:LUP's PEG Ratio is ranked worse than 52.44% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs FRA:LUP: 1.93
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Luye Pharma Group (FRA:LUP) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Luye Pharma Group PEG Ratio Related Terms
Luye Pharma Group PEG Ratio Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Luye Pharma Group (FRA:LUP) has a PEG Ratio of 1.79 as of Jul. 03, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Luye Pharma Group and its competitors. This is 127% above median its historical median of 0.79. Over the past decade, Luye Pharma Group's PEG Ratio has ranged from 0.39 to 5.22. According to the industry distribution chart, Luye Pharma Group ranks #183 out of 349 companies in the Drug Manufacturers industry, placing it in the top 52.4%.
Is Luye Pharma Group's PEG Ratio too high?
Luye Pharma Group's current PEG Ratio of 1.79 is 127% above median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 5.22. The Drug Manufacturers industry median PEG Ratio is 1.71. Luye Pharma Group's value of 1.79 is 4.7% above this industry median. Based on the distribution chart, Luye Pharma Group ranks #183 out of 349 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #183 out of 349 companies for PEG Ratio. This places Luye Pharma Group in the lower half of its industry. The industry median PEG Ratio is 1.71. Luye Pharma Group's value of 1.79 is 4.7% above this benchmark. Historically, Luye Pharma Group's own PEG Ratio has ranged from 0.39 to 5.22 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 1.71, Luye Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current PEG Ratio of 1.79 is 4.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current PEG Ratio is 1.79, which is 127% above median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current PEG Ratio is 1.79, which is 127% above median its 10-year median of 0.79 and 4.7% above the Drug Manufacturers industry median of 1.71. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current PEG Ratio is 1.79 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
PEG Ratio: 1.79 (127% above median its 10-year median of 0.79)
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
Industry Position: 4.7% above the Drug Manufacturers median (#183 of 349)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
